Infliximab for psoriasis - 29/08/11
Abstract |
This review summarizes the use of inflximab in psoriasis and other immune-mediated inflammatory disorders (IMIDs). The magnitude and speed of the response to infliximab monotherapy of moderate to severe psoriasis vulgaris is substantial, being similar to those achieved with cyclosporin. In contrast with cyclosporin, clinical improvement after the initial 3 intravenous influsions of infliximab is maintained for as long as 6 months in approximately half the patients with the absence of any additional treatment. Additionally, infliximab monotherapy normalizes keratinocyte proliferation and differentiation and markedly decreases epidermal inflammation. These results provide a convincing argument for the role of TNF-⍺ in the pathogenesis of psoriasis and for the clinical development of infliximab for the treatment of psoriasis.
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: Centocor, Inc, a COSAT grant from the Johnson and Johnson Focused Giving Program, general support of the Clinical Research Center by Merck, Inc, and a grant from the Dr David Ju Foundation. Disclosure: Dr Gottlieb is both a consultant and investigator for Amgen, Centocor, Connetics, Biogen, Genentech, Xoma, Wyeth, Cellgate, Boeringer-Ingelheim, Quatrex, Pfizer, and Novartis. She is a consultant for Enanta, Celgene, Beiersdorf, and Roche Pharmaceuticals and an investigator for Aventis. Dr Gottlieb does not own any stock in these companies nor in any companies with which she has a business relationship. |
Vol 49 - N° 2S
P. 112-117 - août 2003 Retour au numéro
Article précédent
- Etanercept: An overview
- Ben Goffe, Jennifer Clay Cather
- Combining the new biologic agents with our current psoriasis armamentarium
- Mark Lebwohl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?